NCT04170426尚未招募1 期
Phase 1/2a Clinical Study for Subjects With Rheumatoid Arthritis (RA) Using Multiple Dose Intravenous Infusions of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 54
- 主要终点
- Adverse Events and Sever Adverse Events
研究概览
简要总结
This is an investigational new drug clinical trial for combined Phase 1 dose escalation study and Phase 2a randomized, placebo controlled and double blinded study using intravenous injection of autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis patients. All subjects are monitored for safety (adverse events/severe adverse events) and evaluated for RAPID3, DAS28 and ACR20 regarding AdMSCs up to 52 weeks study duration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must pass communicable disease screen tests for HIV, syphilis, Hepatitis B and C Consistent with American Rheumatism Association-European League Against Rheumatism (ACR/EULAR) 2010 rheumatoid arthritis classification criteria
- •Active Rheumatoid Arthritis, see RA functional status of class I-IV
- •Patients must meet at least one of the following: > 6 swollen joints and ≥ 6 involved joints (tenderness, swelling, deformity, pain on motion, or decreased motion) and morning stiffness ≥ 45 minutes based on 68 joint count.
- •Patients must also meet at least one of the following: rheumatoid factor (RF) > 15 IU/mL or > 1:16, C-reactive protein (CRP) > 2.0 mg/dL, Erythrocyte Sedimentation Rate (ESR) > 30 mm/hour, and anti-cyclic citrullinated protein (Anti-CCP) > 20 U/mL, TNFα > 2.8 pg/mL.
- •Patients must have failed anti-rheumatoid drug due to adverse event or inefficacy for at least 12 week and at least 4 weeks on stable dose of methotrexate ≤ 25 mg/week, or leflunomide ≤ 20 mg/day, or sulfasalazine ≤ 3 g/day, or steroids (Prednisone <10 mg/day).
- •For other medications, patients must be on the stable dose for at least 4 weeks prior to study entry in order to preclude changes to patient medication while participating on the study to ensure that a medication change could become a confounding factor in data interpretation.
- •All patients must be clinically stable with no significant changes in health status a minimum of at least 4 weeks prior to randomization and confirming patient eligibility
排除标准
- •Current or prior to treatment
- •Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start
- •Evidence of immune suppression related to prior/current therapy
- •> 10% change in delivered monthly dose of anti-rheumatoid medications within 4 weeks prior to this stem cell infusion
- •Use of a new or additional anti-rheumatoid medication within 6 weeks prior to this stem cell infusion
- •Use of other stem cell therapy within 12 weeks prior to this stem cell therapy
- •Unwillingness or inability to comply with study procedures
- •Concurrent Conditions
- •Clinically active malignant disease
- •Severe bladder or thrombotic disorder
- •History of known pulmonary embolism or known secondary anti-phospholipid syndrome
- •Known or suspected hypersensitivity to any components used to culture or store the AdMSCs, e.g. sulfur or sulfonamide
- •Known or suspected antibodies to any components used to culture the AdMSCs, e.g. BSA and sulfur containing products (e.g., DMSO)
- •Active infection at time of planned study treatment start
- •Age related pathology likely to inhibit study participation or completion
- •Major trauma or surgery within 14 days of study treatment start
- •Mental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study
- •Alcohol, drug, or medication abuse within one year before study treatment start
- •Any condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study
- •Irreversible severe end organ failure, such as heart failure/attack, stroke, liver and renal failure
- •Heavy smokers, bed-bound patients, patients or family history with hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc.
- •Laboratory Parameters
- •Hepatic impairment, defined as any of ALT, AST, LDH or bilirubin > 2 x the upper limit of normal (ULN) range according to local laboratory standards
- •Renal impairment, defined as serum creatinine > 133 mmol/L (1.5 mg/dL)
- •Positive virology/serology for human immunodeficiency virus (HIV), hepatitis B (HBsAg positive), hepatitis C and/or syphilis
- •Pregnancy / contraception
- •Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study
结局指标
主要结局
Adverse Events and Sever Adverse Events
时间窗: 52 weeks
The total number of adverse events and severe adverse events related and non-related with AdMSCs will be recorded to indicate the safety and tolerability.
次要结局
- Efficacy of Celltex AdMSCs(52 weeks)
研究者
相似试验
已完成
2 期
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT00902369Asahi Kasei Pharma Corporation130
终止
1 期
Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's SyndromeSharp's SyndromeRheumatoid ArthritisSystemic Lupus ErythematosusNCT02741362Arkansas Heart Hospital2
招募中
1 期
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic ArthritisRheumatoid Arthritis (RA)Psoriatic Arthritis (PsA)NCT06628206LAPIX Therapeutics Inc.48
Unknown
1 期
Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) PatientsRheumatoid ArthritisNCT02665910Jiangsu HengRui Medicine Co., Ltd.48
已完成
2 期
A Study of ARRY-438162 in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT00650767Array Biopharma, now a wholly owned subsidiary of Pfizer201